amendment will be granted or denied by the Director of Personnel or, for records maintained by the Inspector General, the Inspector General. If the request is granted, the Director of Personnel, or, the Inspector General, for records maintained by the Inspector General, shall promptly make any correction of any portion of the record which the individual believes is not accurate, relevant, timely, or complete. If, however, the request is denied, the Director of Personnel shall inform the individual of the refusal to amend the record in accordance with the individual's request and give the reason(s) for the refusal. In cases where the Director of Personnel or the Inspector General has refused to amend in accordance with an individual's request, he or she also shall advise the individual of the procedures under § 201.29 of these regulations for the individual to request a review of that refusal by the full Commission or by an officer designated by the Commission.

5. Paragraphs (a) through (d) of § 201.29 are revised to read as follows:

§ 201.29 Commission review of request for correction or amendment to record.

(a) The individual who disagrees with the refusal of the Director of Personnel or the Inspector General to amend the record may request a review of the refusal by the Commission. All requests for review of refusals to amend records should be addressed to the Chairman, United States International Trade Commission, 500 E Street, SW., Washington, DC 20436, and shall clearly indicate both on the envelope and in the letter that it is a Privacy Act review request.

(b) Not later than 30 days (Saturdays, Sundays, and Federal legal public holidays excluded) from the date on which the Commission receives a request for review of the Director of Personnel's or the Inspector General's refusal to amend the record, the Commission shall complete such a review and make a final determination thereof unless, for good cause shown, the Commission extends the 30-day period.

(c) After the individual's request to amend his or her records has been reviewed by the Commission, if the Commission agrees with the Director of Personnel's or the Inspector General's refusal to amend the record in accordance with the individual's request, the Commission shall: (1) Notify the individual in writing of the Commission's decision; (2) advise the individual that he or she has the right to file a concise statement of disagreement with the Commission which sets forth his or her reasons for disagreement with the refusal of the Commission to amend the records; and (3) notify the individual of his or her legal right to judicial review of the Commission's final determination.

(d) In any disclosure, containing information about which the individual has filed a statement of disagreement, the Director of Personnel, or, for records maintained by the Inspector General, the Inspector General, shall clearly note any portion of the record which is disputed and shall provide copies of the statement and, if the Commission deems it appropriate, copies of a concise statement of the reasons of the Commission for not making the amendments requested, to persons or other agencies to whom the disputed record has been disclosed.

6. Paragraph (b) of § 201.30 is revised to read as follows:

§ 201.30 Commission disclosure of record to person other than the individual to whom it pertains.

(b) Except for disclosures either to officers and employees of the Commission, or, to contractor employees who, in the Inspector General's or the Director of Personnel's judgment, are acting as federal employees, who have a need for the record in the performance of their duties, and any disclosure required by 5 U.S.C. § 552, the Director of Personnel shall keep an accurate accounting of: (1) The date, nature, and purpose of each disclosure of a record to any person or to another agency under paragraph (a) of this section; and (2) the name or address of the person or agency to whom the disclosure is made.

Issued: May 15, 1995.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 95–12360 Filed 5–18–95; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 146

[Docket No. 94N–0452]

RIN 0905–AC48

Canned Fruit Nectars; Proposal to Revoke the Stayed Standard of Identity; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule, correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a proposed rule that appeared in the **Federal Register** of April 21, 1995 (60 FR 19866). The document proposed to revoke the standard of identity for canned fruit nectars. The document was published with an inadvertent error in the preamble section. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Nannie H. Rainey, Center for Food Safety and Applied Nutrition (HFS–158), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–5099.

In FR Doc. 95–9949, appearing on page 19866 in the **Federal Register** of Friday, April 21, 1995, the following correction is made:

1. On page 19867, in the third column, under ''**IV. Request for Comments**'', line 2, ''June 20'' is corrected to read ''July 5''.

Dated: May 10, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–12294 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 201

[Docket No. 92N–0311]

Topical Drug Products Containing Benzoyl Peroxide; Required Labeling; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to July 17, 1995, the comment period for the proposed rule to include additional labeling (warning and directions) for all topically-applied acne treatment drug products containing benzoyl peroxide, which appeared in the **Federal Register** of February 17, 1995 (60 FR 9554). FDA is taking this action in response to a request to extend the comment period.

DATES: Written comments by July 17, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: William E. Gilbertson, Center for Drug Evaluation and Research (HFD–810), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–5000.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 17, 1995 (60 FR 9554), FDA issued a proposed rule to include additional labeling (warning and directions) for all topically-applied acne treatment drug products containing benzoyl peroxide. Interested persons were given until May 18, 1995, to submit written comments on the proposal.

In response to the proposal, the Nonprescription Drug Manufacturers Association (NDMA) requested a 2-month extension of the comment period. NDMA states that the request was on behalf of member companies who manufacture and distribute over-the-counter (OTC) acne drug products containing benzoyl peroxide. NDMA indicated that it intended to comment on FDA's proposal to require additional labeling on acne drug products at the request of its Benzoyl Peroxide Study Group. NDMA stated that it needed more time to document fully questions about certain facts included in the proposal. NDMA added that the precedent-breaking nature of the agency's proposal demanded careful scrutiny and thoughtful consideration and that coordination of the Benzoyl Peroxide Study Group's efforts in these regards was time-consuming.

FDA has carefully considered the request and acknowledges the uniqueness of the proposal. The agency believes that additional time for comment is in the public interest and will be of assistance in establishing labeling that will help consumers safely use drug products containing benzoyl peroxide for the treatment of acne. Accordingly, the comment period is extended to July 17, 1995.

Interested persons may, on or before July 17, 1995, submit to the Dockets Management Branch (address above) written comments regarding the proposal. Three copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 16, 1995.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 95–12399 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 896

[Docket No. 83N–0193]

RIN 0905–AD83

Performance Standard for the Infant Apnea Monitor; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to August 21, 1995, the comment period on the proposed rule that published in the **Federal Register** of February 21, 1995 (60 FR 9762). The document proposed to establish a mandatory performance standard for infant apnea monitors, which are a subset of breathing frequency monitors, also called neonatal apnea monitors. The infant apnea monitor is a system intended for use on infants to detect cessation of breathing. This action is based on a request from industry.

DATES: Written comments by August 21, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: James J. McCue, Center for Devices and Radiological Health (HFZ–84), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–4765.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 21, 1995 (60 FR 9762), FDA published a proposed rule to establish a mandatory performance standard for infant apnea monitors, which are a subset of breathing frequency monitors, also called neonatal apnea monitors. The infant apnea monitor is a system intended for use on infants to detect cessation of breathing. FDA believes that a performance standard is necessary to ensure that infant apnea monitors accurately and reliably detect the absence of effective respiration and provide an alarm in such cases.

Interested persons were invited to comment by May 22, 1995. FDA received one request from industry to extend the comment period for 90 days. The request stated that this timeframe would allow sufficient time to gather the necessary data to develop effective comments.

FDA is extending the comment period for 90 days to ensure adequate time for preparation of comments. Accordingly, FDA finds under section 520(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(d)) that there is good cause for such an extension.

Interested persons may, on or before August 21, 1995, submit to the Dockets Management Branch (address above) written comments regarding this notice. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 10, 1995.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 95–12293 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[PS–013–88]

RIN 1545–AL57

Certain Publicly Traded Partnerships Treated as Corporations; Correction

AGENCY: Internal Revenue Service, Treasury.

ACTION: Correction to notice of proposed rulemaking and notice of public hearing.

SUMMARY: This document contains corrections to the notice of proposed rulemaking and notice of public hearing (PS–013–88) which was published in the **Federal Register** on Tuesday, May 2, 1995 (60 FR 21475), relating to the classification of certain publicly traded partnerships as corporations.

FOR FURTHER INFORMATION CONTACT: Christopher T. Kelley, (202) 622–3080, (not a toll-free call).

SUPPLEMENTARY INFORMATION:

Background

The notice of proposed rulemaking and notice of public hearing that is the subject of these corrections proposes to add § 1.7704–1 to the Income Tax Regulations relating to the definition of a publicly traded partnership under section 7704(b) of the Internal Revenue Code.

Need for Correction

As published, the notice of proposed rulemaking and notice of public hearing